TrueMark Investments LLC Lowers Stock Position in AbbVie Inc. $ABBV

TrueMark Investments LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 46.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 28,099 shares of the company’s stock after selling 24,281 shares during the period. TrueMark Investments LLC’s holdings in AbbVie were worth $6,506,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Conning Inc. grew its holdings in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after buying an additional 12,690 shares in the last quarter. Diversified Trust Co boosted its position in shares of AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares during the last quarter. Dohj LLC grew its holdings in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares in the last quarter. Permanent Capital Management LP bought a new stake in AbbVie in the third quarter worth $720,000. Finally, Railway Pension Investments Ltd raised its stake in AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after purchasing an additional 211,800 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $219.21 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a market cap of $387.42 billion, a price-to-earnings ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36. The business’s 50 day moving average price is $225.60 and its 200-day moving average price is $217.22.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business earned $3.00 EPS. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analyst Ratings Changes

A number of brokerages have commented on ABBV. Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.